Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $21.67 Average Target Price from Analysts

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $21.67.

A number of brokerages have recently commented on NMRA. Needham & Company LLC restated a “buy” rating and issued a $23.00 price target on shares of Neumora Therapeutics in a report on Wednesday, November 13th. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Neumora Therapeutics in a report on Wednesday, November 13th. JPMorgan Chase & Co. lowered Neumora Therapeutics from an “overweight” rating to a “neutral” rating and cut their price target for the company from $18.00 to $15.00 in a report on Tuesday, November 5th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $29.00 price target on shares of Neumora Therapeutics in a report on Wednesday, September 4th.

Insider Buying and Selling

In other Neumora Therapeutics news, CFO Joshua Pinto sold 28,496 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $11.63, for a total transaction of $331,408.48. Following the transaction, the chief financial officer now owns 210,469 shares of the company’s stock, valued at $2,447,754.47. The trade was a 11.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Matthew K. Fust sold 14,049 shares of the business’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $17.03, for a total value of $239,254.47. Following the transaction, the director now directly owns 20,100 shares in the company, valued at approximately $342,303. This trade represents a 41.14 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 110,538 shares of company stock worth $1,390,513. Corporate insiders own 26.40% of the company’s stock.

Hedge Funds Weigh In On Neumora Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Artal Group S.A. grew its position in shares of Neumora Therapeutics by 14.5% in the first quarter. Artal Group S.A. now owns 2,924,052 shares of the company’s stock valued at $40,206,000 after purchasing an additional 371,350 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Neumora Therapeutics by 54.0% in the third quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company’s stock valued at $26,159,000 after purchasing an additional 694,385 shares during the last quarter. State Street Corp grew its position in shares of Neumora Therapeutics by 65.3% in the third quarter. State Street Corp now owns 1,790,707 shares of the company’s stock valued at $23,655,000 after purchasing an additional 707,409 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in shares of Neumora Therapeutics in the first quarter valued at approximately $10,354,000. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Neumora Therapeutics by 139.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company’s stock valued at $9,224,000 after purchasing an additional 406,891 shares during the last quarter. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Trading Up 0.2 %

NASDAQ:NMRA opened at $9.86 on Wednesday. Neumora Therapeutics has a 1 year low of $8.33 and a 1 year high of $21.00. The stock has a market cap of $1.59 billion, a price-to-earnings ratio of -5.27 and a beta of 3.92. The stock has a 50-day moving average price of $13.04 and a two-hundred day moving average price of $11.46.

Neumora Therapeutics (NASDAQ:NMRA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same quarter in the previous year, the business earned ($1.14) earnings per share. Sell-side analysts forecast that Neumora Therapeutics will post -1.58 earnings per share for the current year.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.